Francesca Tebbutt, 33, from Clunderwen in Wales, spent years unaware of what was causing the condition that left her feeling ...

Initially, the rash vanished swiftly but soon returned, spreading further, leading to prescriptions of even stronger steroids ...

A woman who had a small rash now looks 'like a burns victim' - after she suffered an extreme reaction to a common cream.

A woman who had a small rash now looks 'like a burns victim' - after she suffered an extreme reaction to a common cream.

Medicine company Novartis (NVS) said on Thursday that a late-stage trial evaluating its drug Cosentyx in adults with newly ...

"I looked like a burn victim... even my nephews and nieces were scared of me - they looked at me like I was something out of a horror movie" ...

Background Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in patients with moderate-to-severe plaque psoriasis. Early intervention with guselkumab may result in changes to ...

B-IGA success was reported in 39.0% of patients in the roflumilast foam arm and 7.4% of patients in the vehicle arm (difference, 32.4% [95% CI, 23.3-41.6]). The most common adverse reactions reported ...

Shares of Sun Pharma Advanced Research Company Ltd (SPARC) plunged nearly 20% on Wednesday on the NSE, after the company announced disappointing results from Phase 2 trials of its experimental drug, ...

SPARC share price tumbles 20% as Sun Pharma's arm halts development of Psoriasis drug SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044.

Credit: Arcutis. The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis ...

Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate ...